Online Forums

Our 7th annual update with ECO:FACT on global ESG regulatory and policy developments affecting the Biopharma sector. Olivier Jaeggi, Managing Director and Chairman, Alba González, Senior ESG Expert, and Marta Barretta, Environmental Law Specialist, focus on topics where ESG policy and regulation are evolving, and what’s coming in the global pipeline of ESG regulations that will impact biopharma companies directly or indirectly.

Biopharma–Investor sustainability communications: 2025 state-of-play — Roundtable discussion with biopharma and investor representatives regarding the content and process of sustainability communications, plus early feedback on the updated Biopharma Investor ESG Communications Guidance 5.0.

New biosynthetic methods and a recent USP equivalence ruling are driving the move away from Horseshoe Crab blood-derived testing reagents—impacting biodiversity, innovation, and supply chains. Jay Bolden (Eli Lilly), Adele Cheli (GSK), and Ryan Phelan (Revive & Restore) shared their work making this change happen and previewed the new Horseshoe Crab Scorecard.

A conversation with the Co-founder and Co-CEO of EcoVadis, Pierre-François Thaler. EcoVadis was founded in 2007 and has grown into a globally trusted provider of business sustainability ratings, with a network of more than 150,000 rated companies. Pierre-François and team will give insights into their assessment approach, and – very timely – their talks with the European Union regarding the CSDDD.

RepRisk is one of the world’s leading data providers for ESG and Business Conduct, identifying and assessing material ESG risks for corporations based on purely external sources. RepRisk supports investment and financing decisions by some of the world’s largest banks, asset managers and sovereign wealth funds, and many well-known corporate Ratings, Award Schemes, and Index providers embed RepRisk data in their evaluations, including S&P Dow Jones Indices, Bloomberg, CDP, FTSE Russell, Corporate Knights, and Ethisphere.

Our 6th annual update with EcoFact on global Regulatory and ESG policy developments. The online forum presented a deep dive into current and emerging ESG regulations that will affect our sector. Reporting requirements, due diligence regulations, climate transition planning, and nature-related risks were all part of the discussion, along with updates on emerging topics like the link between ESG and AI.

A focused group of Biopharma sustainability leaders and Biopharma sector investors convened for a direct conversation about the sector’s highest priority ESG/Sustainability topics, sparked by initial group survey results. The Workshop provided input towards our next public update of the Biopharma Investor ESG Communications Guidance.

This was an in-person event.

Harald Nusser, a seasoned healthcare executive with global experience in health equity and social business, opened our discussion about Biopharma and Human Rights with a focus on the right to health. Additional perspectives were shared by BSRT colleagues from Hikma, Organon, Pfizer, and Roche.

Jens Reissmann, Project Lead for CSRD at Bayer, shares their project strategy and experience with CSRD and Taxonomy Implementation.